Oyster Point Pharma Inc., of Princeton, N.J., priced its public offering of 3.75 million shares at $28 per share, grossing the company $105 million. The underwriters have a 30-day option to purchase an additional 562,500 shares. The company plans to use the proceeds to fund the development of OC-01 and OC-02 and prepare for the commercialization of OC-01, including the initial build-out of a specialty sales organization and to fund general research and development activities, working capital and other general corporate activities. J.P. Morgan Securities LLC, Cowen and Co. LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering, which is expected to close on May 19. Shares of Oyster Point (NASDAQ:OYST) closed down $2.53, or 7.9%, to $29.50 on May 15.
Sutro Biopharma Inc., of South San Francisco, closed its public offering of 12.65 million shares at $7.75 per share, grossing the company approximately $98 million, which Sutro plans to use for clinical development of STRO-001 and STRO-002, development of its technology platform, including manufacturing, to broaden its pipeline of product candidates and for working capital and general corporate purposes. Cowen, Piper Sandler and Wells Fargo Securities acted as joint book-running managers in the offering.
TG Therapeutics Inc., of New York, priced its public offering of 8.5 million shares at $18 per share, grossing the company $153 million, which TG plans to use for the continued development of ublituximab and umbralisib, the potential in-license, acquisition, development and commercialization of other pharmaceutical products and for general corporate purposes. The underwriters have a 30-day option to purchase an additional 1.275 million shares. J.P. Morgan Securities LLC, Jefferies LLC, Evercore Group LLC. and Cantor Fitzgerald & Co. are acting as joint book-running managers for the proposed offering. Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co. LLC are acting as co-managers for the offering, which is scheduled to close on May 19. Shares of TG (NASDAQ:TGTX) closed down 63 cents, or 3.2%, to $19.30 on May 15.